Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial
References (31)
The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase
Diabetes
(1986)The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin dependent diabetes mellitus: the Diabetes Control and Complications Trial
N Engl J Med
(1993)The Prevalence Study. The Lipid Research Clinics Population Studies Data Book. vol. 1
Report of the task force on high blood pressure
Pediatrics
(1979)Metropolitan height and weight tables
Stat Bull Metrop Life Insur Co
(1983)Color photography vs fluorescein angiography in the detection of diabetic retinopathy in the diabetes control and complications trial
Arch Ophthalmol
(1987)- et al.
Do enzymatic analyses of serum triglyceride really need blanking for free glycerol?
Clin Chem
(1991)
Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultra-centrifuge
Clin Chem
The 10-year incidence of overweight and major weight gain in U.S. adults
Arch Intern Med
Report of the National Cholesterol Education Program Expert Panel on Detection, evaluation and treatment of high blood cholesterol in adults
Arch Intern Med
Generalized linear models
et al.Generalized linear models
Two-sample asymptotically distribution-free tests for incomplete multivariate observation
JASA
Cited by (599)
Impact of tirzepatide in a patient with type 1 diabetes and obesity: A case report
2023, Journal of the American Pharmacists AssociationMacrovascular complications: Peripheral artery disease
2023, BIDE's Diabetes Desk Book: For Healthcare ProfessionalsDiabetic dyslipidaemia
2021, Practical Laboratory MedicineA systematic review and dose-response meta-analysis on the efficacy of dapagliflozin in patients with type 1 diabetes mellitus
2021, Pharmacological ResearchCitation Excerpt :Greater HbA1c variability has been associated with increased mortality and earlier hospital admission rates in patients with type-1 DM [32]. Furthermore, long-term insulin therapy has been linked to higher body weight and consequently elevated blood pressure [29,33,34], both of which are serious concerns in this patient group since it may interfere with treatment adherence [35] and can lead to increased mortality [36]. It has also been shown that optimal glycemic control is often underachieved internationally despite improvements in patient education, DM awareness, and improved insulin delivery systems [37–40].
This study was supported in part by the Division of Diabetes, Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, through cooperative agreements and a research contract, and by the National Heart, Lung and Blood Institute, the National Eye Institute, and the National Center for Research Resources, Bethesda, Maryland.